Infantile hemangioma (strawberry hemangioma, true capillary hemangioma) is one of the most common benign vascular tumors in infancy, with an incidence of about 5%-10%, more in girls than in boys, about 3:1; the incidence is higher in premature infants, about 22%. Infantile hemangiomas have unique clinical manifestations: no or slight skin erythema at birth, rapid increase in size from 1 week to 6-9 months after birth called the rapid proliferation period, followed by a slow regression period of 5-10 years; 50% of children completely regress by age 5 and 90% by age 9. Most infantile hemangiomas are superficial skin lesions, but large hemangiomas, especially those with a staged distribution or hemangiomatosis, are at higher risk for complications other than skin lesions and may even be combined with congenital malformations at other sites such as PHACES syndrome, PELVIS syndrome, and SACRAL syndrome. Although 85-90% of hemangiomas in infants and young children can subside spontaneously after the age of 1 year, if they are not treated promptly and scientifically, they can grow rapidly within a short period of time and may lead to limb deformity, disfigurement, ulceration, bleeding, and some lesions such as those located in the respiratory tract, eye, orbit, parotid area, breast area, perineum, and other special areas can also cause respiratory obstruction, visual impairment, heart failure In addition, hemangioma can cause serious complications such as respiratory obstruction, visual impairment, heart failure, coagulation dysfunction and multi-organ failure, which can endanger the life of the child. Therefore, parents should be fully aware of the seriousness of infant hemangioma and should not be indifferent to it, let alone take it lightly and delay treatment. For most infants and children with hemangioma, surgical treatment is not necessary, as long as the growth can be controlled as early as possible (choose the method with little scientific toxic side effects, urea injection is non-toxic and effective), adverse complications can be avoided, and there is no obvious damage to the skin and tissues after natural regression. For a small proportion of congenital non-resolving hemangiomas, elective surgery is performed according to the specific condition. There is also a part of hemangioma combined with thrombocytopenia (Kasabach-Meritt phenomenon, KMP), which can lead to coagulation dysfunction, high risk of bleeding, rapid disease progression, rapid changes in condition, and high mortality; according to foreign studies, the mortality rate of KMP in foreign countries is more than 50%. At present, there is no unified diagnosis and treatment standard for this disease at home and abroad. For KMP with early stage, limited lesions that can be surgically removed, the prognosis is better; for KMP with late diagnosis, long history and unclear boundaries that cannot be surgically removed, the prognosis is worse. Therefore, for KMP, the key is early detection, early diagnosis and early treatment, and the best results are achieved if surgical resection is possible. Vascular malformation is a congenital vascular lesion, both at birth, with progressive development and progressive severity with age, with serious complications such as bleeding, ulceration, coagulation dysfunction, disability, hemorrhagic shock, and disfigurement at a later stage. Treatment is mainly surgical and conservative. Surgery can eradicate the lesion, but the time and method of surgery are decided according to the specific condition. For large and severe vascular malformations, radiofrequency ablation can be applied to reduce the tumor and local injection of sclerosing agent to control the development of the tumor.